NOTABLE ADVANCES in our knowledge of coagulation durinig the past decade. arisinig largely from studies of hemorrhagie diseases, have served to focus renewed attenition on the role of clotting in the pathogenesis and management of atheroniatous disease and thromboembolism.1 More than a centurv ago v. Rokitansky2 postulated that atheroselerosis follows initial fibrin deposition on the vessel wall. This concept has recently been taken up anew by Duguid and others3-9 who studied morphologic sequences in pathologic, or experimentally introduced, intravascular whole-blood clots or fibrin. The theory that localized coagulation on the arterial wall with subsequent organization is, at least in some instances, the initiating factor in atheroselerosis has been extended by Astrup.10 This investigator views coagulation as being normallv in a state of delicate balance. proceeding throughout the vascular system at a very slow rate, and restrained by opposing anticoagulant forces, particularly the fibrinolytic system, which is also ubiquitous in blood and tissues. Fibrinolysins are thought to be constantly removing the end product, fibrin, as it accumulates on the vessel walls. Their failure to function adequately is postulated as contributing to atherogenesis under certain circumstances.
This "encrustation^' theory mierits vi,gorous study in an attempt to elucidate the pathoscheme divided arbitrarily into four sequengenesis of atherosclerosis. Sonie idea of the magnitude of the problem is revealed in table 1, which depicts the current coagulation tial phases. More than 20 distinct factors, both procoagulant and anticoagulant, are now recognized (table 2) . Several more are suspected but are as yet not clearly defined. These factors interact in an extremely complex manner involving protein-protein and protein-ion reactions, which include positive as well as negative feed-back mechanisms controlling the kinetics of clotting. The four phases of coagulation are shown mnore simply ill table 3.
Many questions immediately arise. Since the factors are all present in the circulation, except perhaps for the "foreign" surface, does coagulation actually proceed constantly in the normal subject, although at a very slow smoldering rate? Or is it held in complete abeyanee ready to be triggered only when called upon to serve the needs of hemostasis? If so? which factors are responsible for triggering and speeding up this mechanism in the presence of disease? Are these factors any of the known clotting constituents, or does pathologic triggering or acceleration Table 1 Current Coagulation Schemez' (table 2) . Not included in the scheme are several of the known, or postulated, inhibitors and certain negative feedback mechanisms. In the formulation of the equations no consideration is given to whether the components are involved stoichiometrically or enzymatically.
Heparin Studenits of coagulation have long been concerned with the riddle of why blood does not clot intravascularly despite the fact that all the necessary clotting factors are present except the "foreign" surface. This blood fluidity has been variously attributed to the fact that several first-phase clotting components, e.g., factor V (Ac-globulin), factor IX (PTC), exist in circulating blood in relatively inert precursor form; to the presence of inhibitor-factor combination e.g., Hageman inhibitor ;12 or to natural circulating anticoaguJants such as heparin.
That the nature of the surface to -which blood is exposed is of fundanmental importance in initiating or accelerating the clotting sequenee has long been known. This is elegantly demuonstrable in the "coagulation" of incoagulable congenital afibrinogenemic blood. 13 The sequential changes were essentially norimal when the blood was exposed to ordinary glass in contrast to blood exposed to siliconecoated vessels. Everything is retarded in the latter. In this patient, the third clotting phase the thromibin-fibrinogen interactionhad been deleted by the If the balance is ' "stable, ' ? any induced disequilibrium will most likely be episodic or fleeting (e.g., thrombotic) with early restoration to the original state of equilibrium. If, on the other hand, it is an "unstable"'* balance, the resulting imbalance will lead to progressive collapse of the primary physiologic function (hemorrhage, or extensive thrombosis as the case may be). Or, if the balaiiee is "neutral, "7 the disequilibrating forces may eventually result in a state of equilibrium operating at a level differing from the original (e.g., excessive continuous fibrin deposition).
Aside from the possible significance of coagulation in the origin as well as in the coinplications of atherosclerotic disease, adequate understanding of this mechanism-i is essential to the rational use of anticoagulants and to other aspects of management of thromboe-nbolic disorders. The physician who emplovs these agents must realize clearly that he niav be tampering with a most important and intricate homeostatic mechanism.
The early sequential changes in clotting blood have been considerably clarified by studies on patients with rare and unique coagulation defects. As already mentioned, from observations in incoagulable congenital Another example of feed-back mechanisms serving to maintain coagulation in dynamic equilibrium, is factor V. Uiider the influenlce of a minute amount of fornied thrombin, factor V is rapidly activated thus acceleratinig eoagulation, while at the same time the activated form becomes very labile an-d deteriorates. This results in deceleration of clotting kinetics, since this clotting factor is essential in both the first phase of coagulation (thromboplastin generation) and in the seconid (thrombin elaboration from prothromnbin).
A third example, one currently of practical clinical significance, is the antifibrinolysin in circulating blood. Clearly this balanced inhibitor of the physiologic clot-dissolving system must be overcome if therapeutic thrombolysis is to be effected by administration of active fibrinolysin (plasmin).
Intrinsic Thromboplastin Generation Let us now return to the first stage of coagulation. Our knowledge regarding the essential componets ( More recently investigation of proteolytic activation has been extended to include studies on other clotting factors.36 37 Of many proteases investigated, only trypsin, papain, and ficin could activate highly purified factor VII (proconvertin) and factor X (Stuart). Activation was extremely prompt, progressive, and profound. No thrombin evolved, and calcium was not required. In contrast to the activating effects of these proteases on factors VII and X, plasmin (fibrinolysin) and thrombin were inert, whereas they could activate factor V (Ac-globulin). The activating effect of plasmin was promptly followed by deterioration of factor V.
It is also of interest that tissue thromboplastin resembles trypsin and papain in activation of factors VII and X.39 These observations suggest that the biologic mechanism of thrombin formation, either through intrinsic (blood) thromboplastin or via extrinsic (tissue) thromboplastin, is one of proteolysis.
The possible significance of the proteolytic pathway in the initiation of thrombin formation under pathologic conditions is evident [75] [76] [77] Specifically, factor VII (proconvertin) or factor X (Stuart), or both, were found to be strikingly elevated in the gravid.74 There was a significant correlation with the duration of pregnancy, higher values occurring preponderantly in the last trimester. Plasma prothrombin was less signifieantly altered, although in some subjects the prothrombin also was somewhat elevated.
Following delivery the elevated factor VII level dropped noticeably, usually within 3 to 7 days post partum. Striking elevations were, however, still present in sonie subjects on the fourth or fifth day following delivery, but in all subjects normal values were attained within 6 weeks. As far as factor VII was concerned, the high levels were in actual proconvertin rather than its activated form, convertin. The The thrombus forms in the partially occluded or completely clamped vascular segment, often also distal to the clamps, and it may fill the entire venous tree distal to the single occluding point. The phenomenoni shows no species specificity; homologous or heterologous serum or serum fractions from many species, including human, are effective. Thus, by using a "product" of the coagulation mechanism, Wessler et al. induce a transitory "hypercoagulable" state, which, together with retarded blood flow, results in local clot formation.
One additional cardinal point emerges fromn their work: clot begets clot, thus providing a mnechanism for in vivo clot propagation, if mtot initiation, and creation of a vicious circle.
Of conisiderable interest is the effect of anticoagulation.134 Prior heparinization prevents the seruimi-induced clot, whereas shorttermn dieumnarolization to the extent of 10 per uent protlhroinbin and 1 per cent factor VII activity does not. The degree of heparinization required for protection is an amount sufficienit to double the clotting time. This is f-ully protective although lower levels may afford some protection.
In the light of our work on the profound activation of purified factors II (prothromibin), VII, and X by trypsin, other observa- Which or what combination of, anticoagulants will prove most effective, and how they should be applied on a broad scale in prevention and long-term treatment, awaits longer experienee. It would be expected a priori that any agent that produces a deficit in components functioning in more than one phase of clotting would in general compromise coagulation (as well as hemostasis) more profoundly than drugs that reduce singlephase components. At present, not enough is known to permit a definitive statement as to which clotting factor, or combination of factors, is crucial to the pathogenesis or prevention of thrombotic disease. It is generally accepted that of the coumarin-vulnerable entities (factors II, VII, IX, aiid X), factor II (prothrombin) appears to be least important. As to hemorrhagic complications of eoumarini therapy, however, considerable disagreement exists: according to some observers172 prothrombin is most significant. Others173 claim that factor X is the more important, while some believe measurement of the total activities of all these four factors is the best guide to anticoagulant therapy and its hemorrhagic complications. 
